Gotham Asset Management LLC purchased a new position in shares of bluebird bio, Inc. (NASDAQ:BLUE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 12,687 shares of the biotechnology company’s stock, valued at approximately $1,333,000.

Several other large investors also recently bought and sold shares of the company. Hanseatic Management Services Inc. grew its stake in shares of bluebird bio by 0.3% during the 2nd quarter. Hanseatic Management Services Inc. now owns 10,436 shares of the biotechnology company’s stock worth $1,096,000 after purchasing an additional 27 shares during the period. Teacher Retirement System of Texas grew its stake in shares of bluebird bio by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 3,250 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 53 shares during the period. Cornerstone Capital Management Holdings LLC. grew its stake in shares of bluebird bio by 0.8% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock worth $1,885,000 after purchasing an additional 140 shares during the period. Prudential Financial Inc. grew its stake in shares of bluebird bio by 4.0% during the 2nd quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock worth $408,000 after purchasing an additional 150 shares during the period. Finally, Winfield Associates Inc. grew its stake in shares of bluebird bio by 6.1% during the 2nd quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock worth $296,000 after purchasing an additional 162 shares during the period.

bluebird bio, Inc. (BLUE) opened at 143.30 on Tuesday. bluebird bio, Inc. has a 12-month low of $37.05 and a 12-month high of $143.50. The firm has a 50-day moving average of $127.32 and a 200-day moving average of $102.41. The stock’s market capitalization is $6.53 billion.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.66) by ($0.07). The company had revenue of $16.70 million during the quarter, compared to analysts’ expectations of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company’s revenue for the quarter was up 977.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.59) EPS. Equities research analysts forecast that bluebird bio, Inc. will post ($6.80) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/17/gotham-asset-management-llc-purchases-shares-of-12687-bluebird-bio-inc-blue.html.

A number of research firms have recently weighed in on BLUE. Jefferies Group LLC reaffirmed a “buy” rating on shares of bluebird bio in a research note on Thursday, July 6th. Cantor Fitzgerald set a $39.00 price target on shares of bluebird bio and gave the stock a “sell” rating in a research note on Saturday, June 24th. Evercore ISI raised shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price target on the stock in a research note on Monday. Sanford C. Bernstein began coverage on shares of bluebird bio in a research note on Thursday, July 27th. They set a “market perform” rating and a $109.00 price target on the stock. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $108.00 price target on shares of bluebird bio in a research note on Friday, August 4th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $118.81.

In related news, insider David Davidson sold 3,000 shares of bluebird bio stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $92.37, for a total value of $277,110.00. Following the transaction, the insider now owns 18,977 shares of the company’s stock, valued at approximately $1,752,905.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Philip D. Gregory sold 750 shares of bluebird bio stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $99.00, for a total value of $74,250.00. Following the completion of the transaction, the insider now directly owns 31,234 shares in the company, valued at approximately $3,092,166. The disclosure for this sale can be found here. Insiders sold a total of 131,779 shares of company stock worth $16,038,514 in the last three months. 3.90% of the stock is currently owned by company insiders.

bluebird bio Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.